UroGen Pharma enters its August 10 earnings window with a notable shift in short positioning — bears have trimmed their exposure meaningfully this week, even as the stock consolidates near a month-long high.
The short side has moved more decisively in the past week than at any point in the prior month. Short interest dropped 8% over the last seven days to 13.3% of free float — down from roughly 14.5% when the previous note was filed on July 8, and the clearest directional move since the rally began. That brings it back toward mid-June levels, when short interest briefly dipped before rebuilding. The borrow market remains easy. Availability is running at nearly 492% — almost five shares available for every one currently lent out — and cost to borrow, while ticking up 10% on the week to 0.49%, is still low in absolute terms. The 52-week trough in availability hit 3.7%, so there is no squeeze dynamic in play. Shorts who want out face no structural barrier, and those who want in face no meaningful friction either.
Options traders continue to lean bullish. The put/call ratio is at 0.45, slightly below its 20-day average of 0.49 and well within its normal range — nothing like the extreme readings seen at the one-year low of 0.18 or high of 0.89. The z-score sits at roughly -0.9, meaning options positioning is modestly more call-heavy than usual but not aggressively so. The CMO, Mark Schoenberg, sold $400,000 of stock on July 9 at $40 — the latest in a series of sales that have netted approximately $1.2 million over the past 90 days. Those sales started well below current prices ($27–$30 range in May and June), so part of the pattern reflects opportunistic profit-taking as the stock has rallied sharply rather than any single bearish signal, but the persistence is worth noting.
The Street is broadly constructive but not aggressively so. The consensus sits at Buy, with a mean price target around $37 — now roughly in line with the current $39.19 price, meaning URGN has effectively caught up to where analysts expected it to be. HC Wainwright holds a $45 target and has reiterated Buy twice since May; Oppenheimer raised its target to $40 in May. D. Boral Capital carries a $33 target, which is now below the market price — stale enough that it may be due for a refresh ahead of August results. The bull case rests on the Phase 3 ENVISION data for ZUSDURI and the pipeline path for UGN-103, which the bear case notes won't reach market until 2027, creating a profitability gap in the interim. The EV/EBITDA multiple has compressed sharply, falling more than 40 points over the past 30 days as earnings projections have improved — the 30-day momentum in forward EPS ranks in the 100th percentile of the universe, though the 90-day reading sits at just the 2nd percentile, highlighting how recent and sharp the revision cycle has been.
Among US-listed peers, the week has been notably weaker. NAMS fell 10% and PTCT dropped 12% over the same period that URGN added nearly 4%. TGTX shed 5.5%. That relative outperformance keeps URGN's short score — currently at 64.1 and edging lower across the week from a recent high near 66 — in mild retreat, suggesting some of the bearish pressure that built during June is gradually unwinding.
The key question heading into August 10 is whether URGN can deliver enough on Jelmyto and Zusduri commercial momentum to justify a stock that has now caught up to Street consensus, with UGN-103 still two years from market and the CMO actively selling into every leg of the rally.
See the live data behind this article on ORTEX.
Open URGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
